Global Cooperations
Global Cooperations
EnliTISA is a multi-drug development company and the vision is to develop more effective, safer and better tolerated anti-inflammatory and anti-fibrosis drugs.
Global Cooperations
EnliTISA is a multi-drug development company and the vision is to develop more effective, safer and better tolerated anti-inflammatory and anti-fibrosis drugs. 17 patent applications have been filed. Three patents have been granted respectively in China, in US and in several other territories.
Now, EnliTISA is a clinical stage drug development company. The phase II clinical trial on acute respiratory distress syndrome (ARDS) has been completed in China, in March 2025; the phase Ib clinical trial on radiation-induced oral mucositis is in progress in China; and the phase I study in IPF by subcutaneous injection was completed in Sweden, in December 2024. In the future, EnliTISA could be developed into a full scale pharmaceutical company in China according to the plan of the founders.
The main business model in early stage focuses on out-licensing. In 2021 and 2022, EnliTISA signed license agreement with a leading big pharma in China, Shanghai Pharma. Our out-licensing business model is proven successful through ongoing partnerships, including collaborations with Shanghai Pharma that have generated revenue from 2021 through 2024.
EnliTISA won the silver medal of the 13th China Innovation & Entrepreneurship Competition in 2024, which was a national competition and organized by the Torch High Technology Industry Development Center, Ministry of Industry and Information Technology of China.
COMPANY
EnliTISA is a multi-drug development company and the vision is to develop more effective, safer and better tolerated anti-inflammatory and anti-fibrosis drugs.
Global Cooperations
EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
1The main business model in early stage focuses on out-licensing. In 2021 and 2022, EnliTISA signed license agreement with a leading big pharma in China, Shanghai Pharma. Our out-licensing business model is proven successful through ongoing partnerships, including collaborations with Shanghai Pharma that have generated revenue from 2021 through 2024.
EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
1The main business model in early stage focuses on out-licensing. In 2021 and 2022, EnliTISA signed license agreement with a leading big pharma in China, Shanghai Pharma. Our out-licensing business model is proven successful through ongoing partnerships, including collaborations with Shanghai Pharma that have generated revenue from 2021 through 2024.
EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
1The main business model in early stage focuses on out-licensing. In 2021 and 2022, EnliTISA signed license agreement with a leading big pharma in China, Shanghai Pharma. Our out-licensing business model is proven successful through ongoing partnerships, including collaborations with Shanghai Pharma that have generated revenue from 2021 through 2024.
Tel:+86-021-33758853
Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai
Contact：Dr. Gu Ming
E-mail： bdservice@tisatide.com
Copyright ©2022 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO 沪ICP备2022023966号-1 Powered by www.300.cn